Interestingly, the same biologics—namely anti-IgE, anti–IL-5, and anti–IL-4Rα–have been recently approved for the treatment of severe CRSwNP (while dupilumab was approved first in severe CRSwNP, before asthma), further increasing the relevance of integrating UAD in the management of (severe) asthma. The gene discussed is IL4R; the disease is chronic rhinosinusitis with nasal polyps.